New Polygenic Risk Scores Advance Obesity and Type 2 Diabetes Prediction

Investigators at Mass General Brigham have developed advanced Polygenic Risk Scores (PRSs) designed to predict an individual's risk of developing obesity and Type 2 Diabetes (T2D). These new PRSs integrate genetic findings from over 8.5 million participants globally and demonstrate enhanced predictive capabilities compared to existing disease prediction models.

Development and Scope

The developed metabolic PRSs utilize genetic data from genome-wide association studies (GWAS) drawn from several of the world's largest biobanks. These scores assess risk by focusing on genes associated with 20 different traits related to metabolic function, including fat distribution, insulin control, and glucose regulation, moving beyond traditional metrics such as body mass index (BMI).

Enhanced Predictive Capabilities

The PRSs have demonstrated superior performance in predicting not only the diagnosis of obesity or T2D but also downstream health consequences and the potential need for clinical interventions. The research indicates that these risk scores can identify individuals at high risk for clinical outcomes, including cardiovascular disease and stroke.

Specifically, individuals with a high PRS who were initially healthy were observed to be approximately twice as likely to later require GLP-1 agonist medications or bariatric surgery over a median follow-up period of 5.5 years, compared to those with mid-range PRS scores.

Multi-Ancestry Data Integration

A key aspect of this development involved the utilization of multi-ancestry GWAS data, with a specific focus on non-European populations. This approach enabled the construction of obesity and T2D risk scores that outperformed previous PRS models in African, East Asian, and South Asian individuals.

Future Research Directions

Researchers involved in the project aim to continue refining the understanding of genetic subtypes of T2D and obesity. This ongoing work is intended to improve patient classification and stratification for clinical trials. The ultimate goal is to foster the development of more tailored and effective interventions, facilitate early identification of individuals with a higher genetic susceptibility to poor metabolic health beyond BMI, and enhance prevention and clinical strategies.